The group's principal activity is the discovery, development and commercialization of therapeutics related to the treatment of serious men's health conditions. The group has two product candidates that are in human clinical trials, acapodene and andarine. The group is a development stage company. As on 6-Feb-2004, the group completed an initial public offering.
